<DOC>
	<DOCNO>NCT02855125</DOCNO>
	<brief_summary>This randomize , open-label , Phase 2 study TAS-114 administer combination S-1 , investigate efficacy , safety tolerability TAS-114/S-1 regimen patient advance metastatic NSCLC . The study conduct internationally 2 region : Asian [ Japan ] Western [ Europe US ] . Patients randomize TAS-114/S-1 arm versus S-1 control arm 1:1 ratio .</brief_summary>
	<brief_title>A Randomized Phase 2 Trial TAS-114 Combination With S-1 Versus S-1</brief_title>
	<detailed_description>Randomization take place consent patient complete necessary baseline procedure deem eligible study entry . Treatment assignment do centrally use dynamic allocation method ( bias coin ) via interactive voice/web response system ( IXRS ) stratify : - Geographical region ( Region 1 : Asian [ Japan ] ; Region 2 : Western [ Europe US ] ) - Histological subtypes ( nonsquamous cell carcinoma [ include mixed ] squamous cell carcinoma )</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Age ≥ 18 year old ( ≥ 20 year old Japan ) ; 2 . Histologically diagnose cytologically proven advanced metastatic NSCLC patient , either Stage IIIB/Stage IV disease ( accord Version 7 International Association Study Lung Cancer Staging Manual Thoracic Oncology ) , recurrent disease follow radiation therapy surgical resection ; 3 . Patients receive least 2 prior therapy advance metastatic disease condition , include platinum doublet pemetrexed , docetaxel , immunotherapy , refractory unable tolerate last prior therapy 4 . Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) criterion ( Version 1.1 , 2009 ) ; 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ; 6 . Predicted life expectancy least 3 month ; 7 . Able take medication orally ; 8 . Adequate organ function 9 . Women childbearing potential ( WOCBP ) must negative pregnancy test ( urine serum ) within 7 day prior start study drug . Both male female must agree use effective birth control study ( prior first dose 6 month last dose ) conception possible interval . 10 . Willing able comply require schedule visit study procedure . 1 . Treatment follow within specified time frame prior study drug administration : Major surgery within prior 4 week minor surgery within 7 day ; Radiotherapy extend field within prior 4 week limited field within prior 2 week ; Any anticancer therapy investigational agent within prior 3 week . 2 . A serious illness medical condition 3 . Concomitant treatment follow drug may interact S1 : Sorivudine , brivudine , uracil , eniluracil , folinate/folinic acid , Cimetidine , dipyridamole , nitroimidazoles , include metronidazole misonidazoleMethotrexate , Clozapine , Allopurinol , Phenytoin , Flucytosine , fluorinated pyrimidine antifungal agent , Coumarinderivative anticoagulant 4 . Known hypersensitivity S1 metabolites ( eg , 5FU ) ; 5 . Previous use TAS114 , S1 , 5FU drug ; 6 . A pregnant lactating female possibly pregnant woman , men woman wish child study period ; 7 . A judgment investigator patient inappropriate study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>phase 2 study</keyword>
	<keyword>TAS-114</keyword>
	<keyword>S-1</keyword>
</DOC>